Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Chronobiol Int ; 40(8): 1004-1027, 2023 08.
Article in English | MEDLINE | ID: mdl-37548004

ABSTRACT

Environmental factors, such as sleep restriction, contribute to polycystic ovary syndrome (PCOS) by causing hyperinsulinemia, hyperandrogenism, insulin resistance, and oligo- or anovulation. This study aimed to evaluate the effects of circadian rhythm disruption on reproductive and metabolic functions and investigate the potential therapeutic benefits of MitoQ10 and hot tub therapy (HTT). Sixty female rats were divided into six groups: control, MitoQ10, HTT, and three groups with PCOS induced by continuous light exposure(L/L). The reproductive, endocrine, and structural manifestations ofL/L-induced PCOS were confirmed by serum biochemical measurements, ultrasound evaluation of ovarian size, and vaginal smear examination at week 14. Subsequently, the rats were divided into the L/L (untreated), L/L+MitoQ10-treated, andL/L+HTT-treated groups. At the end of week 22, all rats were sacrificed. Treatmentwith MitoQ10 or HTT partially reversed the reproductive, endocrine, and structural features of PCOS, leading to a decreased amplitude of isolated uterine contractions, ovarian cystic changes and size, and endometrial thickness. Furthermore, both interventions improved the elevated serum levels of anti-Mullerian hormone (AMH), kisspeptin, Fibulin-1, A disintegrin and metalloproteinase with thrombospondin motifs 19 (ADAMTS-19), lipid profile, homeostatic model assessment for insulin resistance (HOMA-IR), oxidative stress markers, androgen receptors (AR) and their transcription target genes, FKBP52 immunostaining in ovarian tissues, and uterine estrogen receptor alpha (ER-α) and PRimmunostaining. In conclusion, MitoQ10 supplementation and HTT demonstrated the potential for ameliorating metabolic, reproductive, and structural perturbations associated with PCOS induced by circadian rhythm disruption. These findings suggest a potential therapeutic role for these interventions in managing PCOS in women.


Subject(s)
Hyperandrogenism , Insulin Resistance , Polycystic Ovary Syndrome , Humans , Female , Rats , Animals , Polycystic Ovary Syndrome/diagnosis , Polycystic Ovary Syndrome/therapy , Hot Temperature , Circadian Rhythm , Hyperandrogenism/therapy
4.
Front Physiol ; 12: 744548, 2021.
Article in English | MEDLINE | ID: mdl-34899377

ABSTRACT

Synchronized uterine receptivity with the time of implantation is crucial for pregnancy continuity. Vitamin D (VD) deficiency has been linked to the failure of implantation. Therefore, we tested the link between the Homeobox transcription factor-10/immunophilin FK506-binding protein 52 (HOXA-10/FKBP52) axis and the uterine receptivity in VD-deficient rats. The effect of VD supplementation at different doses was also investigated. Forty-eight pregnant rats were divided into six groups (eight/group); normal control rats fed with standard chow (control), control rats supplemented with VD (equivalent dose of 400 IU/day) (control-D400). VD-deficient group (DEF) and the three VD deficiency groups with VD supplementation were equivalent to 400, 4,000, and 10,000 IU/day (DEF-D400, DEF-D4000, and DEF-D10000, respectively). The expression levels of HOXA-10/FKBP52, progesterone level, and histological evaluation of decidualization using osteopontin (OSN) and progesterone receptor (PGR) were estimated. An assessment of the uterine contractility was conducted for all rats. This study showed the downregulation of HOXA-10/FKBP52 together with increased amplitude and frequency of the uterine contractility in the DEF group compared to control. VD dose-dependent supplementation restored progesterone/receptor competency, upregulated the expressional response of HOXA-10 and its downstream FKBP52, and improved uterine receptivity and endometrial decidualization at the time of implantation that was documented by increased area% of OSN and the number of implantation beads.

5.
Physiol Rep ; 9(12): e14925, 2021 06.
Article in English | MEDLINE | ID: mdl-34174018

ABSTRACT

BACKGROUND: Preeclampsia is a systemic, multi-organ endotheliopathy, associated with oxidative injury to the blood-brain barrier (BBB). Preeclampsia initiates a cascade of events that include neuroinflammation. Recently, it was documented that Wnt/ß-catenin signaling pathway exerts neuroprotective effects and maintain BBB integrity. We investigate the protective effect of omega-3 against neurovascular complication of preeclampsia and its relation to Wnt/ß-catenin signaling pathway. METHODOLOGY: After confirmation of day 0 pregnancy (G0), 24 adult pregnant female Wistar rats were divided into four groups control pregnant, pregnant supplemented with omega-3, preeclampsia (PE); female rats received N (ω)-nitro-L-arginine methyl ester (L-NAME) (50 mg/kg/day SC from day 7 to day 16 of pregnancy for induction of preeclampsia) and PE rats supplemented with omega-3. The intake of omega-3 started on day zero (0) of pregnancy until the end of the study (144 mg/kg\day orally). RESULTS: We found that omega-3 supplementation significantly improved cognitive functions and EEG amplitude, decreased blood pressure, water contents of brain tissues, sFlt-1, oxidative stress, proteinuria, and enhanced Wnt\ß-catenin proteins. Histological examination showed improved cerebral microangiopathy, increased expression of claudin-1 and -3, CD31, and VEGF in the cerebral cortical microvasculature and choroid plexus in PE rats treated with omega-3. A positive correlation between protein expression level of Wnt \ß-catenin and cognitive functions, and a negative correlation between claudin-5 relative expression, claudin-1 and -3 area % from one side and water content of the brain tissues from the other side were observed. CONCLUSION: Wnt/ß-catenin signaling pathway suspected to have an important role to improve BBB integrity. Neuroprotective, antioxidant, and anti-inflammatory effects of omega-3 were observed and can be suggested as protective supplementation for preeclampsia.


Subject(s)
Blood-Brain Barrier/drug effects , Fatty Acids, Omega-3/pharmacology , Neuroprotective Agents/pharmacology , Pre-Eclampsia/prevention & control , Wnt Signaling Pathway/drug effects , Animals , Blood Pressure/drug effects , Electroencephalography , Fatty Acids, Omega-3/therapeutic use , Female , Neuroprotective Agents/therapeutic use , Open Field Test/drug effects , Pre-Eclampsia/drug therapy , Pregnancy , Rats , Rats, Wistar
6.
Dermatol Ther ; 34(2): e14879, 2021 03.
Article in English | MEDLINE | ID: mdl-33586174

ABSTRACT

Resolvin D1 (RvD1) is an endogenous lipid mediator that originated from docosahexaenoic acid that stimulates a bimodal mechanism in the anti-inflammatory activity in addition to regulation of the inflammatory reaction. The study aimed at assessing the tissue level of RvD1 in psoriasis to study its role in the etiopathogenesis of psoriasis, studying the action of NB-UVB on the level of resolvin D1 in psoriasis, and raising the possibility of using resolvin D1 as a new therapy for psoriasis in the future. This case-control study included 20 psoriasis patients and 20 healthy controls. Patients took narrowband ultraviolet B (NB-UVB) for 36 sessions. Skin biopsies were taken before and after treatment from patients and from controls to assess the expression of RvD1 by a quantitative real-time polymerase chain reaction. Our findings revealed a statistically significant difference (P < .001) between psoriasis patients (either before or after treatment) and controls with lower levels of RvD1 in psoriasis patients. On comparing the RvD1 levels in psoriasis patients before and after treatment, a statistically significant increase was detected after treatment (P < .001). Tissue RvD1 levels in psoriasis patients were lower than healthy controls and increased after NB-UVB treatment in psoriasis patients. Thus, it is suggested that RvD1 might have a role in the etiopathogenesis of psoriasis. Moreover, the significantly up-regulated tissue levels of RvD1 in patients after treatment with NB-UVB highlighted a novel mechanism of phototherapy-mediated response in psoriasis by up-regulating RvD1 level.


Subject(s)
Psoriasis , Ultraviolet Therapy , Case-Control Studies , Docosahexaenoic Acids , Humans , Phototherapy , Psoriasis/diagnosis , Psoriasis/therapy
7.
Photodermatol Photoimmunol Photomed ; 37(4): 306-312, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33404131

ABSTRACT

BACKGROUND: Despite exhaustive research, melanocyte disappearance and the evolution of vitiligo remain enigmatic, and although multi-factorial, oxidative stress appears as a major player. The role of cutaneous cholinergic system in vitiligo pathogenesis has also been reported in some studies. OBJECTIVE: To evaluate and correlate the influence of phototherapy on cutaneous cholinergic system and oxidative stress in vitiligo. METHODS: Acetyl choline (ACh), its receptors; nicotinic (nAChR) and muscarinic (mAChR); acetylcholine esterase (AChE) and H2 O2 levels were estimated in de-pigmented and re-pigmented lesions of 30 vitiligo patients before and after NB-UVB phototherapy and in 30 controls. ACh and H2 O2 levels were measured by colorimetry. AChE and acetylcholine receptors expression were measured by quantitative real-time PCR. RESULTS: Mean ACh and H2 O2 levels were significantly higher in vitiligo lesions before NB-UVB (P < .001) whereas AChE enzyme level was significantly lower (P < .001) compared to both re-pigmented and control skin. Additionally, mean mAChR was significantly higher and mean nAChR was significantly lower in vitiligo lesions before NB-UVB versus controls and re-pigmented skin (P < .001). Also, H2 O2 and AChE showed negative correlation whereas ACh and mAChR showed significant positive correlation. Although all the studied parameters showed significant changes after treatment and subsequent re-pigmentation, a significant difference continued to exist between all vitiligo skin and controls. CONCLUSION: Cholinergic system is strongly involved in vitiligo pathogenesis through H2 O2 inhibition of AChE which could be reversed by NB-UVB. Moreover, the strong activation of mAChRs may reflect genetic and/or acquired errors, direct up-regulation by ACh and H2 O2 or both.


Subject(s)
Ultraviolet Therapy , Vitiligo , Cholinergic Agents , Humans , Oxidative Stress , Skin , Treatment Outcome
8.
Dermatol Ther ; 34(1): e14649, 2021 01.
Article in English | MEDLINE | ID: mdl-33314655

ABSTRACT

Narrowband-ultraviolet B (NB-UVB) is considered one of the main therapeutic tools in vitiligo, which is able to induce repigmentation and halt depigmentation. However, little remains known about the effect of NB-UVB on TYR gene family, the main pigmentary genes, in vitiligo patients. To assess the effect of NB-UVB on expression of some genes related to the pigmentary problem of vitiligo; tyrosinase (TYR), tyrosinase related protein 1 (TYRP1) and tyrosinase related protein 2 (TYRP2), mRNA levels of those genes were quantitatively evaluated by Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) in skin biopsies obtained from 30 patients with nonsegmental vitiligo and five healthy controls. Vitiligo patients were classified into two groups; group 1, involving 12 untreated vitiligo patients and group 2, including 18 vitiligo patients treated by NB-UVB. The levels of TYR, TYRP-1, and TYRP-2 mRNAs in untreated group were significantly lower than in control subjects (P < .001). In NB-UVB treated group, the three genes were significantly higher than in group 1 (P < .001), however, they were still significantly lower than in the control subjects (P < .001). A significant positive correlation was detected between TYR and TYRP-2 genes in group 2 (P = .03). This study demonstrated that mRNA level of TYR, TYRP-1, and TYRP-2, which decreased in vitiligo, was significantly increased upon treatment with NB-UVB. Accordingly, the mechanism of depigmentation in vitiligo disease and repigmentation by NB-UVB treatment may be related to the changes in the expression of these genes.


Subject(s)
Intramolecular Oxidoreductases/genetics , Membrane Glycoproteins/genetics , Monophenol Monooxygenase/genetics , Oxidoreductases/genetics , Ultraviolet Therapy , Vitiligo , Humans , RNA, Messenger/genetics , Retrospective Studies , Treatment Outcome , Vitiligo/diagnosis , Vitiligo/genetics , Vitiligo/therapy
9.
Mol Biol Rep ; 47(11): 8523-8533, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33051752

ABSTRACT

In 1990, pregabalin was introduced as a novel antiepileptic drug that acts by binding selectively to the alpha-2-delta subunits of voltage-gated calcium channels resulting in increasing neuronal GABA levels and inhibiting the release of exciting neurotransmitters. The aim of our study is to assess the hazardous effects of prolonged high-dose pregabalin (like that abused by addicts) on testes and to clarify the potential causative mechanisms. The current study was conducted on 70 adult male Wistar albino rats which were divided into 7 groups. In our study we evaluated the effect of pregabalin, at concentrations 150 and 300 mg/kg/day for 90 days, on hormones; FSH, LH, testosterone and prolactin secretion. Our study also evaluated the expression of apoptosis-related genes BAX and BCL2 in testicular tissue in addition to the western blotted analysis of p38 Mitogen activated protein kinases (p38 MAPK). The levels of reduced glutathione, malondialdehyde and superoxide dismutase were also measured. Pregabalin decreased testosterone level while FSH, LH and prolactin showed a significant increase. It also produced genotoxicity through reversal of the BAX/BCL2 ratio; increased p38 MAPK level and induction of oxidative stress markers. The concomitant administration of vitamin E significantly reduced all the previously mentioned biochemical and hormonal adverse effects caused by pregabalin. Pregabalin can adversely affect male fertility particularly in addicts and patients who are being treated with it for long periods as those suffering from neuropathies and seizures. Antioxidants like vitamin E could have a role in amelioration.


Subject(s)
Apoptosis/drug effects , Hormones/metabolism , Oxidative Stress/drug effects , Pregabalin/pharmacology , Testis/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Anticonvulsants/pharmacology , Dose-Response Relationship, Drug , Follicle Stimulating Hormone/metabolism , Gene Expression/drug effects , Glutathione/metabolism , Male , Malondialdehyde/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats, Wistar , Superoxide Dismutase/metabolism , Testis/cytology , Testis/metabolism , Testosterone/metabolism , Time Factors , bcl-2-Associated X Protein/genetics , bcl-2-Associated X Protein/metabolism
10.
Tissue Cell ; 67: 101441, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32949962

ABSTRACT

Despite the emerging concerns about the hepatotoxic risks associated with Zinc oxide nanoparticles (ZnO NPs), yet, the morphological and molecular alterations associated with these extensively-used nanoparticles remain to be elucidated. Thus, the current study has been designed to analyze the effect of ZnO NPs on the hepatic histopathological and immunohistochemical changes, along with the modulation of the oxidative-stress induced JNK/p38MAPK and the STAT-3 signalling. The study also explored the potential protective role of selenium against those alterations. ZnO NPs disrupted the hepatic architecture, elevated the serum liver enzyme alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) levels and caused dose-dependent decrease in the activity of the antioxidant enzymes glutathione-peroxidase, superoxide dismutase and catalase along with an increase in the lipid peroxidation product malondialdehyde. ZnO NPs also increased the area of immune-reactivity of the apoptotic protein bax and decreased the area of immune-reactivity of the anti-apoptotic protein bcl2 together with augmentation of the hepatic caspase 3 gene expression. The role of selenium in ameliorating the hepatotoxicity, oxidative stress injury, and apoptosis induced by ZnO-NPs, along with its role in modulating the JNK/p38MAPK and the STAT-3 signalling and improving the histopathological hepatic changes, offers selenium as a promising adjunctive therapy in individuals subjected to high concentrations of ZnO NPs especially in cases of extensive occupational, medicinal and industrial exposure.


Subject(s)
Liver/pathology , Nanoparticles/administration & dosage , Nanoparticles/toxicity , Selenium/pharmacology , Zinc Oxide/administration & dosage , Zinc Oxide/toxicity , Administration, Oral , Animals , Apoptosis/drug effects , Gene Expression Regulation/drug effects , Hepatocytes/drug effects , Hepatocytes/metabolism , Immunohistochemistry , Liver/drug effects , Liver/physiopathology , MAP Kinase Kinase 4/genetics , MAP Kinase Kinase 4/metabolism , Male , Nanoparticles/ultrastructure , Nitric Oxide Synthase Type II/metabolism , Oxidative Stress/drug effects , Rats, Sprague-Dawley , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , bcl-2-Associated X Protein/metabolism , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolism
11.
Naunyn Schmiedebergs Arch Pharmacol ; 393(9): 1635-1648, 2020 09.
Article in English | MEDLINE | ID: mdl-32377769

ABSTRACT

Pregabalin abuse has become an emerging concern; thus, the current study has been designed to study the neurotoxic hazards of prolonged high-dose of pregabalin (akin to that abused by addicts) and to evaluate the effect of alpha tocopherol as a possible ameliorating agent. The current study evaluated the brain neurotransmitters; dopamine, glutamate, and norepinephrine. The study also assessed the expression of the apoptosis-related markers Bax, Bcl2, and caspase 3. Western-blotted analysis of the three major mitogen-activated protein kinases (MAPKs), the c-JUN N-terminal kinase (JNK), the p38 MAPK, and the extracellular signal-regulated kinase (ERK), has also been performed. The study also evaluated oxidative stress via assessment of the cortical tissue levels of reduced glutathione and malondialdehyde and the activity of superoxide dismutase. Histopathological examination and histomorphometric evaluation of the darkly degenerated cortical neurons have also been performed. Pregabalin in high doses (150 mg/kg/day and 300 mg/kg/day) disrupted the ERK/JNK/p38-MAPK signaling, reversed the bax/bcl2 ratio, and induced oxidative stress. It also diminished the release of dopamine, glutamate, and norepinephrine and increased the count of degenerated neurons. Alpha tocopherol treatment significantly attenuated the deleterious effects induced by pregabalin. The role of alpha tocopherol in ameliorating the oxidative stress injury, and apoptosis induced by pregabalin, along with its role in normalizing neurotransmitters, modulating the ERK/JNK/p38-MAPK signaling pathways and improving the histopathological cortical changes, offers alpha tocopherol as a promising adjunctive therapy in patients undergoing prolonged pregabalin therapy as those suffering from prolonged seizures and neuropathies.


Subject(s)
Antioxidants/pharmacology , Apoptosis/drug effects , Cerebral Cortex/drug effects , Mitogen-Activated Protein Kinases/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/prevention & control , Oxidative Stress/drug effects , Pregabalin/toxicity , alpha-Tocopherol/pharmacology , Animals , Apoptosis Regulatory Proteins/metabolism , Cerebral Cortex/enzymology , Cerebral Cortex/pathology , Male , Neurons/enzymology , Neurons/pathology , Neurotoxicity Syndromes/enzymology , Neurotoxicity Syndromes/etiology , Neurotoxicity Syndromes/pathology , Phosphorylation , Rats, Wistar , Signal Transduction
13.
Ann Anat ; 222: 94-102, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30521949

ABSTRACT

Management of diabetic wounds remains a major challenge in the medical field, mostly due to incompetent outcomes of treatments. Curcumin has been documented as anti-inflammatory, antioxidant, antimicrobial and antineoplastic agent in addition to wound healing activities. However, its poor aqueous solubility and impaired skin permeation handicap its topical pharmaceutical usage. Hydrogel loaded curcumin nanoparticle (Cur-NP/HG) could overcome this pitfall and enable extended topical delivery of curcumin. Rat model of diabetes mellitus (DM) type I was induced using single injection of 70mg/kg streptozotocin (STZ) followed by full thickness skin wound. Rats were divided into 4 groups. GpI: control non-diabetic, GpII: diabetic non-treated, GpIII: diabetic treated with topical curcumin hydrogel (Cur/HG) and GpIV: diabetic treated with topical Cur-NP/HG. Histological assessment of epidermal regeneration, dermo-epidermal junction, leukocyte infiltration and collagen deposition, in addition to immunohistochemical staining for vascular endothelial growth factor (VEGF) and aquaporin-3 (AQP3) were performed. Diabetic rat possessed impaired wound closure, persistence of inflammation and decreased collagen deposition as compared to non-diabetic control. Application of Cur/HG induced partial improvement of the healing process in diabetic rats. Cur-NP/HG treatment provoked obvious improvement of the healing process with complete re-epithelization, intact dermo-epidermal junction, reorganization of the dermis with significantly increased collagen deposition and VEGF and AQP3 expression. These results illustrated that Cur-NP/HG have effectively improved the healing process in diabetic skin wound with substantial differences in the wound healing kinetics compared to wounds that received Cur/HG.


Subject(s)
Curcumin/therapeutic use , Diabetes Mellitus, Type 1/complications , Wound Healing/drug effects , Administration, Topical , Animals , Aquaporin 3/biosynthesis , Collagen/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Type 1/pathology , Epithelium/drug effects , Epithelium/growth & development , Hydrogels , Immunohistochemistry , Male , Nanoparticles , Rats , Regeneration/drug effects , Skin/pathology , Vascular Endothelial Growth Factor A/biosynthesis
14.
Arch Physiol Biochem ; 124(5): 461-467, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29308676

ABSTRACT

OBJECTIVE: We hypothesised that vitamin D has a beneficial renal protective effect from diabetic nephropathy (DN). METHODS: Four rat groups were included: normal control (control), type 2 diabetes for eight weeks (DM), treated group with angiotensin receptor blocker losartan (DM + L), and vitamin D-treated group started from the onset of diabetes (DM + Vit D). RESULTS: In the both treated groups, we found a significant (p < .05) reduction in the renal pro-inflammatory and profibrotic markers induced by diabetes. Vitamin D caused more reduction in monocyte chemoattractant protein-1 (MCP-1), transforming growth factor (TGFß-1), and renin-angiotensin levels that gave better kidney function compared to the DM + L group. CONCLUSION: Vitamin D may have a valuable role in the renal protective effect from DN, this may occur via expression of its VDR, Klotho and blocking renin-angiotensin activation, so vitamin D should be considered as a target in renal prophylactic measures against DN.


Subject(s)
Diabetic Nephropathies/prevention & control , Dietary Supplements , Gene Expression Regulation , Glucuronidase/metabolism , Kidney/metabolism , Renal Insufficiency/prevention & control , Vitamin D/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Biomarkers/blood , Biomarkers/metabolism , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/therapy , Diabetic Nephropathies/immunology , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/physiopathology , Down-Regulation , Glucuronidase/chemistry , Glucuronidase/genetics , Kidney/drug effects , Kidney/immunology , Kidney/physiopathology , Klotho Proteins , Losartan/therapeutic use , Male , Random Allocation , Rats, Wistar , Receptors, Calcitriol/agonists , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Renal Insufficiency/complications , Renal Insufficiency/immunology , Renal Insufficiency/metabolism , Renin-Angiotensin System/drug effects , Reproducibility of Results
15.
PLoS One ; 12(7): e0181535, 2017.
Article in English | MEDLINE | ID: mdl-28727797

ABSTRACT

Resveratrol (RSV), a polyphenolic compound and naturally occurring phytoalexin, has been reported to exert cardio-protective effects in several animal studies. However, the outcome of initial clinical trials with RSV was less effective compared to pre-clinical studies. Therefore, RSV treatment protocols need to be optimized. In this study we evaluated prophylactic versus therapeutic effect of resveratrol (RSV) in mitigating doxorubicin (Dox)-induced cardiac toxicity in rats. To investigate prophylactic effects, RSV was supplemented for 2 weeks along with Dox administration. After 2 weeks, Dox treatment was stopped and RSV was continued for another 4 weeks. To study therapeutic effects, RSV treatment was initiated after 2 weeks of Dox administration and continued for 4 weeks. Both prophylactic and therapeutic use of RSV mitigated Dox induced deterioration of cardiac function as assessed by echocardiography. Also RSV treatment (prophylactic and therapeutic) prevented Dox induced myocardial damage as measured by cardiac enzymes (LDH and CK-MB) in serum. Which was associated with decrease in Dox induced myocardial apoptosis and fibrosis. Interestingly our study also reveals that prophylactic use of RSV was more effective than its therapeutic use in mitigating Dox induced apoptosis and fibrosis in the myocardium. Therefore, prophylactic use of resveratrol may be projected as a possible future adjuvant therapy to minimize cardiotoxic side effects of doxorubicin in cancer patients.


Subject(s)
Doxorubicin/toxicity , Heart/drug effects , Protective Agents/administration & dosage , Stilbenes/administration & dosage , Animals , Apoptosis/drug effects , Biomarkers/blood , Cardiotoxicity/drug therapy , Cardiotoxicity/prevention & control , Creatine Kinase, MB Form/blood , Drug Administration Schedule , Drug Evaluation, Preclinical , Echocardiography , Heart/diagnostic imaging , Immunohistochemistry , L-Lactate Dehydrogenase/blood , Male , Myocardium/metabolism , Myocardium/pathology , NFATC Transcription Factors/metabolism , Random Allocation , Rats, Wistar , Resveratrol
16.
EXCLI J ; 16: 138-150, 2017.
Article in English | MEDLINE | ID: mdl-28435433

ABSTRACT

Peripheral nerve injuries can cause disabilities, social or economic problems. Melatonin, the secretory product of the pineal gland has antioxidant and anti-inflammatory actions. The aim of the present study was to investigate the effect of melatonin on the recovery of sciatic nerve after injury, comparing its effect when given in the light or the dark periods. Forty adult male Albino rats were allocated into four groups: control, nerve injury, nerve injury + melatonin given at light and nerve injury + melatonin given at dark. Nerve injury was initiated by clamping the sciatic nerve. Sciatic functional index (SFI) was measured preoperatively and postoperatively. Melatonin was given daily for six weeks. Recovery of the function was analyzed by functional analysis, electrophysiological analysis and biochemical measurement of Superoxide dismutase (SOD), Interleukin 1-beta (IL-1 ß), Nerve growth factor (NGF), and bcl-2. Melatonin improved SFI, nerve conduction velocity (NCV) and the force of gastrocnemius muscle contraction as compared to the untreated rats. SOD activity, NGF, and bcl-2 were significantly increased, while IL-1ß was significantly decreased after melatonin treatment as compared to the untreated injury group. SFI reached the control level; muscle contraction and IL-1B were significantly improved in the group treated with melatonin in the dark. Melatonin fastened the neural recovery and may be used in the treatment of nerve injury and it induced better nerve regeneration when the rats were treated during the dark period.

17.
Neuromolecular Med ; 17(2): 121-36, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25680935

ABSTRACT

Stress is any condition that impairs the balance of the organism physiologically or psychologically. The response to stress involves several neurohormonal consequences. Glutamate is the primary excitatory neurotransmitter in the central nervous system, and its release is increased by stress that predisposes to excitotoxicity in the brain. Memantine is an uncompetitive N-methyl D-aspartate glutamatergic receptors antagonist and has shown beneficial effect on cognitive function especially in Alzheimer's disease. The aim of the work was to investigate memantine effect on memory and behavior in animal models of acute and repeated restraint stress with the evaluation of serum markers of stress and the expression of hippocampal markers of synaptic plasticity. Forty-two male rats were divided into seven groups (six rats/group): control, acute restraint stress, acute restraint stress with Memantine, repeated restraint stress, repeated restraint stress with Memantine and Memantine groups (two subgroups as positive control). Spatial working memory and behavior were assessed by performance in Y-maze. We evaluated serum cortisol, tumor necrotic factor, interleukin-6 and hippocampal expression of brain-derived neurotrophic factor, synaptophysin and calcium-/calmodulin-dependent protein kinase II. Our results revealed that Memantine improved spatial working memory in repeated stress, decreased serum level of stress markers and modified the hippocampal synaptic plasticity markers in both patterns of stress exposure; in ARS, Memantine upregulated the expression of synaptophysin and brain-derived neurotrophic factor and downregulated the expression of calcium-/calmodulin-dependent protein kinase II, and in repeated restraint stress, it upregulated the expression of synaptophysin and downregulated calcium-/calmodulin-dependent protein kinase II expression.


Subject(s)
Behavior, Animal/drug effects , Excitatory Amino Acid Antagonists/therapeutic use , Hippocampus/drug effects , Memantine/therapeutic use , Neuronal Plasticity/drug effects , Neuroprotective Agents/therapeutic use , Restraint, Physical/adverse effects , Spatial Memory/drug effects , Stress, Physiological/drug effects , Stress, Psychological/drug therapy , Acute Disease , Animals , Anxiety/blood , Anxiety/drug therapy , Anxiety/etiology , Behavior, Animal/physiology , Biomarkers/blood , Brain-Derived Neurotrophic Factor/biosynthesis , Brain-Derived Neurotrophic Factor/genetics , Calcium-Calmodulin-Dependent Protein Kinase Type 2/biosynthesis , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Drug Evaluation, Preclinical , Excitatory Amino Acid Antagonists/pharmacology , Freezing Reaction, Cataleptic/drug effects , Freezing Reaction, Cataleptic/physiology , Gene Expression Regulation/drug effects , Grooming/drug effects , Grooming/physiology , Hippocampus/chemistry , Hippocampus/physiopathology , Hydrocortisone/blood , Interleukin-6/blood , Male , Maze Learning/drug effects , Maze Learning/physiology , Memantine/pharmacology , Nerve Tissue Proteins/biosynthesis , Nerve Tissue Proteins/genetics , Neurogenesis/drug effects , Neuroprotective Agents/pharmacology , Rats , Rats, Wistar , Spatial Memory/physiology , Stress, Physiological/physiology , Stress, Psychological/blood , Stress, Psychological/etiology , Stress, Psychological/physiopathology , Synaptophysin/biosynthesis , Synaptophysin/genetics , Tumor Necrosis Factor-alpha/blood
SELECTION OF CITATIONS
SEARCH DETAIL